SBIO250117P20000
- 0.00
- 0.000.00%
Alps Etf Trust Medical Breakthroughs Etf Newsroom
Verona Pharma Analyst Ratings
Denali Therapeutics Receives FDA Breakthrough Therapy Designation For Tividenofusp Alfa In Treatment Of Hunter Syndrome (MPS II)
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Verona Pharma Shares Are Trading Higher Following Q4 Financial Results.
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Shares Are Trading Lower After the Company Announced Topline Results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial Evaluating EIF2B Agonist DNL343 in the Treatment of Amyotrophic Lateral Sclerosis Did Not Meet Its...
Verona Posts Early Sales Figures for Q4 and 2024
HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $87
Denali Therapeutics Analyst Ratings
Biggest Stock Movers Tuesday: NARI, DNLI, and More
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
William Blair Initiates Coverage On Denali Therapeutics With Outperform Rating
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Axsome Therapeutics Analyst Ratings
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Axsome Completes Phase 3 Trials for AXS-05 in Alzheimer's Agitation, Plans FDA Submission for Alzheimer's Agitation Drug in 2025